Category: Press Release

Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East

perrin2024-09-29T02:20:50+00:00

OncoHelix will now offer the validated ClarityDX Prostate Risk Score to healthcare providers and their patients suspected of having aggressive prostate cancer.
ClarityDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer.

EDMONTON, Alberta & CALGARY, Alberta–Nanostics. Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and OncoHelix a leader in precision diagnostics, today announced their partnership to provide ClarityDX Prostate® to healthcare providers and men in the Middle East.

OncoHelix provides advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi. This facility is a joint venture between OncoHelix and Burjeel Holdings, one of the largest healthcare providers in the Middle East. The OncoHelix-coLAB facility will now also provide Nanostics’ ClarityDX Prostate diagnostic tool to men at risk of having aggressive prostate cancer. The addition of this test will further enhance patient diagnostics and treatment outcomes in the region.

“Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East really shows how relevant Alberta-developed technology has become to the world,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early. We want all men to benefit from early detection leading to better outcomes.”

Press Release

Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle Eastperrin2024-09-29T02:20:50+00:00

Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the US

perrin2024-09-29T02:23:12+00:00

EDMONTON, Alberta–Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and Protean Biodiagnostics Inc. (Protean) today announced their partnership to provide CDX Prostate in the United States.

CDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or an abnormal Digital Rectal Exam (DRE).

“This agreement with Protean is a huge milestone for Nanostics – we can now provide CDX Prostate to men in the US,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “When used as a reflex test, CDX Prostate is a powerful tool to help identify men with aggressive prostate cancer sooner, leading to better outcomes while also minimizing the negative effects associated with overdiagnosis of the disease.”

“At Protean, we are dedicated to providing access to the best-in-class precision medicine solutions,” said Dr. Anthony Magliocco, CEO of Protean BioDiagnostics. “We are excited to be able to provide CDX Prostate as part of our cancer screening program”.

Press Release

Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the USperrin2024-09-29T02:23:12+00:00

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontario

perrin2024-06-05T14:30:41+00:00

EDMONTON, AB, June 5, 2024 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is thrilled to announce today that men can now provide blood samples for its ClarityDX Prostate test at LifeLabs collection sites across British Columbia, Saskatchewan, and Ontario.

ClarityDX Prostate uses biological data, clinical information, and machine learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

“We are very happy that we can now bring a powerful tool in prostate cancer screening to men and their healthcare providers in BC, Saskatchewan, and Ontario“, said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “When a doctor orders this test for their patient, they will receive accurate information about his risk of aggressive prostate cancer, helping make informed treatment decisions and avoid unnecessary invasive prostate biopsies.”

ClarityDX Prostate is available in British Columbia, Saskatchewan, and Ontario as a laboratory-developed test from Nanostics Clinical Laboratory in Edmonton, Alberta. In these provinces, tests are ordered, analyzed, and reported to the prescribing healthcare provider by Nanostics.

Go to www.nanosticsdx.com for more information and to order ClarityDX Prostate. Please direct all inquiries about the ClarityDX Prostate test to Nanostics via email at [email protected] or telephone 1-800-672-2027. ClarityDX Prostate is also available in Alberta from Nanostics as well as in Quebec from CDL Laboratories.

Click on the link below to read the full press release.

Press Release English

Nanostics Prostate Cancer Screening Test, ClarityDX Prostate®, becomes accessible to men in British Columbia, Saskatchewan, and Ontarioperrin2024-06-05T14:30:41+00:00

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer

perrin2024-05-22T12:15:29+00:00

Quebec-based CDL Laboratories will now offer the validated ClarityDX Prostate risk score to healthcare providers and their patients suspected of having aggressive prostate cancer.
ClarityDX Prostate combines biological and clinical information using AI-powered learning to generate a risk score for aggressive prostate cancer.

EDMONTON, ALBERTA – May 22 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, signed an agreement with Quebec-based CDL Laboratories (CDL) to expand access to the ClarityDX Prostate® to men and their healthcare providers.

ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy or not following a high prostate-specific antigen (PSA) test result.

Click on the link below to read the full press release.

Press Release English

Press Release French

Nanostics partners with CDL Laboratories to Provide Access to ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancerperrin2024-05-22T12:15:29+00:00

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test

perrin2024-04-23T12:23:50+00:00

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test
ClarityDX Prostate is a blood test that combines biological and clinical information using machine learning to generate a risk score for aggressive prostate cancer

EDMONTON, ALBERTA – April 23 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics’ ClarityDX Prostate® test in North America.

Funds raised through the UAIF will go towards expanding access to ClarityDX Prostate across North America and supporting the expansion of its product pipeline, including the development of ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test.

ClarityDX Prostate is currently available in Canada as a laboratory-developed test. For more information or to order the test please visit nanosticsdx.com.

Click below to read the full press release.

Press Release

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Testperrin2024-04-23T12:23:50+00:00

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases

perrin2024-04-11T17:16:42+00:00

Nanostics and Alberta Health Services (AHS) agreement enables collaboration with AHS data scientists to develop new tools to improve the diagnosis of urological diseases.
This collaboration will leverage Alberta’s comprehensive digital healthcare assets to improve patient care while satisfying all AHS privacy concerns.

EDMONTON, ALBERTA – April 9th – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is excited to announce a partnership with Cancer Care Alberta, Alberta Health Services (AHS) to leverage advanced data analytics from Connect Care and the Cancer Care Alberta Data Environment for Cancer Inquiries and Decisions (DECIDe). This agreement will streamline access to Connect Care’s powerful and consolidated “one record, one patient, one health clinical information system” to help drive diagnostic and prognostic innovations in urological care in Alberta.

Click below to read the full press release.

Press Release

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseasesperrin2024-04-11T17:16:42+00:00

Nanostics Launches ClarityDX Prostate Test in Alberta to Significantly Improve Prostate Cancer Screening

perrin2024-01-10T22:12:10+00:00

EDMONTON, ALBERTA – September 28 – Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta. This innovative blood test marks a significant advancement in prostate cancer screening. It provides critical support to men, aged 40 to 75, and their physicians in making more informed decisions, with 3X the accuracy, about whether a biopsy is required following a high prostate-specific antigen (PSA) test result.

According to Dr. John D. Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta, “This test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk.” Notably, research shows that adding ClarityDX Prostate to the patient care pathway could reduce unnecessary prostate biopsies by up to 35% and yield significant cost savings.

Click below to read the full press release.

Press Release

Nanostics Launches ClarityDX Prostate Test in Alberta to Significantly Improve Prostate Cancer Screeningperrin2024-01-10T22:12:10+00:00

Nanostics Clinical Lab Granted Provisional CPSA Accreditation

perrin2023-09-18T16:18:46+00:00

CPSA https://cpsa.ca/facilities-clinics/accreditation/

With this provisional accreditation from the College of Physicians and Surgeons of Alberta (CPSA), Nanostics clinical laboratory in Edmonton can now begin providing its ClarityDX Prostate test to patients.

EDMONTON, AB, September 07, 2023 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that the College of Physicians and Surgeons of Alberta (CPSA) granted provisional accreditation to Nanostics Clinical Laboratory in Edmonton, Alberta, Canada. This important achievement means that Nanostics’ Clinical Laboratory, led by Medical Laboratory Director, Dr. Todd McMullen, can start providing the ClarityDX Prostate® test to patients.

“We are thrilled to receive CPSA accreditation because we can offer our test from our new clinical lab in Edmonton,” said John Lewis, CEO of Nanostics. “This is another major step towards ensuring men facing prostate cancer have access to the best tools that can aid them in managing this devastating disease.”

The ClarityDX Prostate test, validated in men from five clinical sites across Canada, the United States, and Czechia, is a simple and rapid test that accurately predicts the risk of having clinically significant prostate cancer. ClarityDX Prostate is intended to be used by men with elevated levels of PSA and is designed to help physicians and patients make a more informed decision on whether or not to proceed with a biopsy.

CPSA ensures the safety and quality of medical and diagnostic testing services in Alberta through an independent accreditation program. Any Alberta laboratory that performs and reports diagnostic tests to guide patient care needs to be CPSA accredited. It’s a rigorous assessment process based on Quality Management Systems, which are recognized by international healthcare external evaluation organizations.

“Nanostics’ has always been dedicated to exceptional operational standards with a strong commitment to quality performance” said Todd McMullen, Medical Laboratory Director of Nanostics. “CPSA accreditation highlights our commitment to quality and will provide patients with the confidence they need to trust our services.”

Press Release

Nanostics Clinical Lab Granted Provisional CPSA Accreditationperrin2023-09-18T16:18:46+00:00

Nanostics Announces New Medical Laboratory Director Todd McMullen

perrin2023-06-13T13:30:24+00:00

EDMONTON, AB, June 13, 2023 /CNW/ – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX^® platform technology, announced today the appointment of Dr. Todd McMullen as the company’s new Medical Laboratory Director. In this role, Dr. McMullen will lead the accreditation and future operations of Nanostics’ new clinical laboratory in Edmonton, Alberta, Canada. Opening in the summer of 2023, Nanostics’ clinical laboratory will provide testing services to support the Canadian market.

Dr. McMullen received his M.D. from the University of Toronto and his Ph.D. in Biochemistry from the University of Alberta. Todd brings more than 25 years of academic research and medical directorship experience across multiple disease areas to Nanostics. He will support the strategy, direction, and execution of Nanostics’ clinical development programs and lead its medical affairs activities.

“We welcome Todd McMullen as Nanostics’ Medical Laboratory Director. Todd’s experience and insights will be invaluable as we launch our prostate cancer test, ClarityDX Prostate,” said John Lewis, CEO of Nanostics. “Prostate cancer remains one of the leading causes of cancer-related deaths in men, and we have shown that ClarityDX Prostate can improve patient care by more accurately identifying men with clinically significant prostate cancer.”

The appointment comes on the heels of exciting momentum for Nanostics as it readies for the launch of its ClarityDX Prostate^® test to accurately detect clinically significant prostate cancer in men with elevated PSA levels. ClarityDX Prostate uses a proprietary algorithm that combines data from biological and clinical biomarkers to generate a risk score for clinically significant prostate cancer. The ClarityDX Prostate test is intended to be used by men with elevated levels of PSA and is designed to help physicians and patients make a more informed decision on whether or not to proceed with a biopsy.

Press Release

Nanostics Announces New Medical Laboratory Director Todd McMullenperrin2023-06-13T13:30:24+00:00

News Release: Recognizing 10 years of philanthropic support for prostate cancer research

perrin2022-10-13T05:02:22+00:00

Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.

Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs Chair in Translational Oncology, a position to be held by researcher Dr. John Lewis. For the last 10 years, Dr. Lewis has held the Frank and Carla Sojonky Chair in Prostate Cancer Research, made possible by a $5 million endowment from the Bird Dogs. Taking over from Dr. Lewis in this position will be surgeon-scientist, Dr. Adam Kinnaird.

News Release

News Release: Recognizing 10 years of philanthropic support for prostate cancer researchperrin2022-10-13T05:02:22+00:00

Follow Us

Contact Us